Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease

Correia, Chase; Briones, M.R.; Guo, Rong; Ostrowski, Rochella A.

doi:10.1007/s10067-018-04421-0

Cited by 31 publications

(17 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eight out of these studies demonstrated significant results with the ORs ranging from 1.98 to 44.5 (table 2). Excluding one study, 47 which conducted a stratified analysis based on the level of the autoantibody titre and thus was not combined, a meta-analysis of 19 out of these 20 studies demonstrated that the presence of anti-CCP antibody was significantly associated with RA-ILD with an OR of 2.10 (95% CI: 1.59 to 2.78) with moderate heterogeneity (χ 2 =29.7, p=0.04, I 2 =39%) (figure 2).…”

Section: Association Of Anti-ccp Antibody With Ra-ild Univariate Resultsmentioning

confidence: 99%

Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody

Kamiya¹,

Panlaqui

2021

BMJ Open

View full text Add to dashboard Cite

ObjectiveTo clarify the risk of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) related to anti-cyclic citrullinated peptide (CCP) antibody.Eligibility criteriaPatients with RA with and without ILD were eligible. The primary outcome was the prevalence or incidence of ILD. Primary studies of any design aside from a case report were eligible.Information sourcesMedline, EMBASE, Science Citation Index Expanded and Cochrane Central Register of Controlled Trials were searched from the inception through 12 November 2019.Data extraction and risk of biasTwo reviewers independently selected eligible reports, extracted relevant data and assessed risk of bias using a modified Quality in Prognostic Studies tool.Data synthesisMeta-analysis was conducted using a random-effects model.Quality of evidenceThe Grades of Recommendation, Assessment, Development and Evaluation system was applied.ResultsAmong 29 out of 827 records retrieved through electronic databases and four additional reports identified from other sources, 29 studies were focused for the review. A total of 10158 subjects were included and the mean age at inclusion was between 45.8 and 63.9 years. The mean RA duration was between 4.3 and 14.9 years. The positivity of anti-CCP antibody ranged from 50.7% to 95.8%. All studies except for two were deemed as high risk of bias. A pooled analysis of univariate results demonstrated that the presence of anti-CCP antibody was significantly associated with RA-ILD with an OR of 2.10 (95% CI: 1.59 to 2.78). Similarly, the titre of anti-CCP antibody was significantly higher for RA-ILD with a standardised mean difference of 0.42 (95% CI: 0.20 to 0.65). These results were confirmed by multivariate analysis in the majority of studies and consistent by any subgroup and sensitivity analyses.ConclusionThe presence and higher titres of anti-CCP antibody were suggested to be significantly associated with an increased risk of RA-ILD. However, the quality of evidence was rated as low or very low.

show abstract

Section: Association Of Anti-ccp Antibody With Ra-ild Univariate Resultsmentioning

confidence: 99%

Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody

Kamiya¹,

Panlaqui

2021

BMJ Open

View full text Add to dashboard Cite

show abstract

“…Fifth, the disease duration, activity or severity of RA and COPD were not considered, and the medications used were not examined. Finally, interstitial lung disease (ILD) is known to be associated with RA, and the presence of ACPAs also affects ILD development, which was not investigated 27 …”

Section: Discussionmentioning

confidence: 99%

Prevalence of chronic obstructive pulmonary disease in patients with rheumatoid arthritis: A cross‐sectional study

et al. 2021

View full text Add to dashboard Cite

Objective Rheumatoid arthritis (RA) and chronic obstructive pulmonary disease (COPD) are both chronic inflammatory diseases; the prevalence of COPD in RA patients is known to be high. However, the prevalence of both RA and COPD differs according to sex; the relationship between RA and COPD may also vary according to sex. Therefore, we investigated the prevalence of COPD and its association in patients with RA in Korea by sex. Methods We conducted a nationwide cross‐sectional study using data from the Korea National Health and Nutrition Examination Survey. A total of 12 417 men and 15 878 women were included. In this study, RA was defined as physician diagnosed or currently under RA treatment. COPD was defined based on spirometry results, chronic symptoms, and smoking history. Multivariable logistic regression models were employed and we calculated the odds ratios (ORs) and 95% confidence intervals (CIs) for COPD prevalence in patients with RA. Results The prevalence of COPD was 15.5% in men with RA, 3.5% in women with RA, 7.8% in men without RA, and 2.2% in women without RA. After adjustment for potential confounding variables, including smoking status, RA was significantly associated with COPD in men (OR 2.16, 95% CI 1.06‐4.40), but not in women (OR 1.58, 95% CI 0.81‐3.10). Conclusions In Korea, the prevalence of COPD was high in patients with RA of both sexes; RA and COPD was significantly likely to be associated in men, but not in women.

show abstract

“…There are also reports that support this hypothesis, as ILD can precede joint damage in some subsets of RA-ILD patients [17]. Correia et al [18] reported that the higher ACPA titres are also associated with increasing prevalence of ILD. In their study, two thousand thirty patients were included.…”

Section: Acpamentioning

confidence: 91%

Rheumatoid arthritis–associated interstitial lung disease: an overview of epidemiology, pathogenesis and management

Dai

Wang

et al. 2020

Clin Rheumatol

View full text Add to dashboard Cite

Interstitial lung disease (ILD) accounts for the major cause of morbidity and mortality in rheumatoid arthritis (RA). However, little is known of the pathogenesis, diagnosis and treatment of RA-associated ILD. In this review, we describe our present understanding and ongoing research in RA-ILD. Its aetiology does appear to associate with anti-cyclic citrullinated peptide antibodies, MUC5B mutation and smoking. Another focus of this article is on recent diagnostic methods in RA-ILD. Compared with other methods, high-resolution computed tomography (HRCT) imaging is a main method for the evaluation of ILD in RA patients. Pulmonary function is better suited for assessing progression. An important topic relates to therapeutic intervention. Disease-modifying anti-rheumatic drugs (DMARDs) in RA lack strong evidence in the onset or worsening of ILD. The available literature support that methotrexate, leflunomide, abatacept and rituximab play beneficial roles in the prevention and treatment of RA-ILD.

show abstract

Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease

Cited by 31 publications

References 13 publications

Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody

Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody

Prevalence of chronic obstructive pulmonary disease in patients with rheumatoid arthritis: A cross‐sectional study

Rheumatoid arthritis–associated interstitial lung disease: an overview of epidemiology, pathogenesis and management

Contact Info

Product

Resources

About